Artificial Intelligence in the Cancer Market
Product Overview
For years, artificial intelligence (AI) has caught society's interest and generated excitement about its potential tenhance our lives. AI is already a part of our everyday lives, as well as our interactions with media, transportation, and communications. AI applications in healthcare are gaining traction as a way tenhance illness diagnosis, management, and the creation of successful treatments. Given the enormous number of patients diagnosed with cancer and the large quantity of data collected during treatment, AI applications timprove oncologic care are of particular interest. During medical operations, artificial intelligence assists medical practitioners in retrieving information, interpreting pictures, and planning therapy. It alsmakes healthcare workers' jobs easier.
Market Highlights
Global Artificial Intelligence in Cancer market is expected tproject a notable CAGR of XX.X% in 2030
Global Artificial Intelligence in Cancer tsurpass USD XXXX billion by 2030 from USD XXXX billion in 2020 at a CAGR of XX.X% in the coming years, i.e., 2021-30. Some of the main variables helping revenue growth in the market include an increase in the inflow of patient health-related digital data, growing need tminimize healthcare cost, and rising desire for tailored medication. Another important reason that has increased the need tstudy and identify illnesses in their early stages is the rise in the prevalence of chronic diseases such as cancer. Deep learning technology would make it simple tanticipate illnesses based on past health data. Furthermore, content analytics, Natural Language Processing (NLP) technologies, and Artificial Intelligence (AI) can aid in the patient's rapid diagnosis.
Recent highlights in the Global Artificial Intelligence in Cancer Market
In August 2020, Digital Diagnostics Inc., formerly known as IDx, purchased 3Derm Systems Inc. The acquisition intended texpand 3DermTriage's dermatological telemedicine capabilities and prepare its autonomous AI skin cancer diagnosis device, 3DermSpot, for FDA approval.
In September 2019, For creating applications for its Edison AI platform, GE Healthcare signed a Cooperation agreement with five local Chinese software development companies-12Sigma Technologies, Shukun Technology, Biomind, YITU Technology, and Yizhun Medical AI. These important partners are expected tdeliver mature software products that would enable GE Healthcare's digital transition tgsmoothly.
Global Artificial Intelligence in Cancer Market: Segments
Targeted Therapy segment tgrow with the highest CAGR during 2020-30
Global Artificial Intelligence in Cancer market is segmented by Product Type intSurgery, Radiotherapy, Chemotherapy, Immunotherapy, Phototherapy, Targeted therapy, Gene Therapy, Sonodynamic Therapy. Among these Targeted Therapy is expected thave the highest growth in the forecast period. This can be attributed tthe discovery of cancer cells' molecular targets. Recent developments in cellular technology and gene therapy have improved our understanding of tumor cells and their metabolism at the molecular level, prompting the development of tailored cancer medication treatments.
Lung cancer segment tgrow with the highest CAGR during 2020-30
Global Artificial Intelligence in Cancer market is segmented by Cancer Type intLung, Breast, Melanoma, Colorectal, Prostate and others. The high prevalence of breast cancer across the world is a key contributor tthis segment's substantial share. However, the lung cancer category is anticipated tgrow the most throughout the projection period. The rising prevalence of lung cancer throughout the world, as well as the growing demand for early detection, are driving this segment's rise.
Market Dynamics
Drivers
Expansion of companies
Thelp end-users overcome the shortage of radiologists, deliver value-based care, early disease detection and diagnosis, and maintain a competitive edge in the market, companies are increasingly focusing on expanding their geographical reach and introducing newer, innovative solutions through various strategies, including partnerships, product launches, and collaborations.
Restraint
Medical professionals' reluctance tuse AI-based technology
Due tthe rapid rise of digital health, healthcare practitioners may now aid patients with innovative treatment techniques. AI technologies provide doctors with tools thelp them diagnose and treat patients more efficiently. Doctors, on the other hand, have shown a reluctance tadopt new technology. For example, there is a widespread belief among medical professionals that AI will eventually replace physicians. Doctors and radiologists feel that qualities like empathy and persuasion are human abilities, and that technological advancements cannot totally eliminate the need for a doctor. Furthermore, there is fear that patients may become overly reliant on these technologies and will foregimportant in-person treatments, thereby jeopardizing long-term doctor-patient relationships.
Global Artificial Intelligence in Cancer Market: Key Players
Microsoft Corporation
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
NVIDIA
IBM
Intel
Siemens Healthineers
GE Healthcare
Digital Diagnostics
Xilinx
InformAI
Enlitic
Day ZerDiagnostics
Aidence
Butterfly Network, Inc.
Prognos
Zebra Medical Vision
Global Artificial Intelligence in Cancer Market: Regions
Global Artificial Intelligence in Cancer market is segmented based on regional analysis intfive major regions. These include North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. Global AI in Cancer in North America held the largest market share in the year 2020. However, The APAC market is expected tgrow at the fastest rate over the forecast period, owing temerging market growth strategies, improved medical diagnostic infrastructure, an ageing population, rising cancer prevalence, favorable government initiatives for AI in healthcare, and an increase in the number of COVID-19 positive patients.
Global Artificial Intelligence in Cancer Market is further segmented by region into:
North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany and Rest of Europe
Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – China, Japan, Australia and Rest of APAC
Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
Global Artificial Intelligence in Cancer Market report alscontains analysis on:
Artificial Intelligence in Cancer Segments:
By Surgery
Radiotherapy
Chemotherapy
Immunotherapy
Targeted Therapy
Phototherapy
Gene Therapy
Sonodynamic Therapy
By Cancer Type
Breast cancer
Lung cancer
Melanoma cancer
Colorectal cancer
Prostate cancer
Others
By End User
Diagnosis
Therapy
Prognosis
Health Management
Research
Artificial Intelligence in Cancer Market Dynamics
Artificial Intelligence in Cancer Market Size
Supply & Demand
Current Market Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
For years, artificial intelligence (AI) has caught society's interest and generated excitement about its potential tenhance our lives. AI is already a part of our everyday lives, as well as our interactions with media, transportation, and communications. AI applications in healthcare are gaining traction as a way tenhance illness diagnosis, management, and the creation of successful treatments. Given the enormous number of patients diagnosed with cancer and the large quantity of data collected during treatment, AI applications timprove oncologic care are of particular interest. During medical operations, artificial intelligence assists medical practitioners in retrieving information, interpreting pictures, and planning therapy. It alsmakes healthcare workers' jobs easier.
Market Highlights
Global Artificial Intelligence in Cancer market is expected tproject a notable CAGR of XX.X% in 2030
Global Artificial Intelligence in Cancer tsurpass USD XXXX billion by 2030 from USD XXXX billion in 2020 at a CAGR of XX.X% in the coming years, i.e., 2021-30. Some of the main variables helping revenue growth in the market include an increase in the inflow of patient health-related digital data, growing need tminimize healthcare cost, and rising desire for tailored medication. Another important reason that has increased the need tstudy and identify illnesses in their early stages is the rise in the prevalence of chronic diseases such as cancer. Deep learning technology would make it simple tanticipate illnesses based on past health data. Furthermore, content analytics, Natural Language Processing (NLP) technologies, and Artificial Intelligence (AI) can aid in the patient's rapid diagnosis.
Recent highlights in the Global Artificial Intelligence in Cancer Market
In August 2020, Digital Diagnostics Inc., formerly known as IDx, purchased 3Derm Systems Inc. The acquisition intended texpand 3DermTriage's dermatological telemedicine capabilities and prepare its autonomous AI skin cancer diagnosis device, 3DermSpot, for FDA approval.
In September 2019, For creating applications for its Edison AI platform, GE Healthcare signed a Cooperation agreement with five local Chinese software development companies-12Sigma Technologies, Shukun Technology, Biomind, YITU Technology, and Yizhun Medical AI. These important partners are expected tdeliver mature software products that would enable GE Healthcare's digital transition tgsmoothly.
Global Artificial Intelligence in Cancer Market: Segments
Targeted Therapy segment tgrow with the highest CAGR during 2020-30
Global Artificial Intelligence in Cancer market is segmented by Product Type intSurgery, Radiotherapy, Chemotherapy, Immunotherapy, Phototherapy, Targeted therapy, Gene Therapy, Sonodynamic Therapy. Among these Targeted Therapy is expected thave the highest growth in the forecast period. This can be attributed tthe discovery of cancer cells' molecular targets. Recent developments in cellular technology and gene therapy have improved our understanding of tumor cells and their metabolism at the molecular level, prompting the development of tailored cancer medication treatments.
Lung cancer segment tgrow with the highest CAGR during 2020-30
Global Artificial Intelligence in Cancer market is segmented by Cancer Type intLung, Breast, Melanoma, Colorectal, Prostate and others. The high prevalence of breast cancer across the world is a key contributor tthis segment's substantial share. However, the lung cancer category is anticipated tgrow the most throughout the projection period. The rising prevalence of lung cancer throughout the world, as well as the growing demand for early detection, are driving this segment's rise.
Market Dynamics
Drivers
Expansion of companies
Thelp end-users overcome the shortage of radiologists, deliver value-based care, early disease detection and diagnosis, and maintain a competitive edge in the market, companies are increasingly focusing on expanding their geographical reach and introducing newer, innovative solutions through various strategies, including partnerships, product launches, and collaborations.
Restraint
Medical professionals' reluctance tuse AI-based technology
Due tthe rapid rise of digital health, healthcare practitioners may now aid patients with innovative treatment techniques. AI technologies provide doctors with tools thelp them diagnose and treat patients more efficiently. Doctors, on the other hand, have shown a reluctance tadopt new technology. For example, there is a widespread belief among medical professionals that AI will eventually replace physicians. Doctors and radiologists feel that qualities like empathy and persuasion are human abilities, and that technological advancements cannot totally eliminate the need for a doctor. Furthermore, there is fear that patients may become overly reliant on these technologies and will foregimportant in-person treatments, thereby jeopardizing long-term doctor-patient relationships.
Global Artificial Intelligence in Cancer Market: Key Players
Microsoft Corporation
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
NVIDIA
IBM
Intel
Siemens Healthineers
GE Healthcare
Digital Diagnostics
Xilinx
InformAI
Enlitic
Day ZerDiagnostics
Aidence
Butterfly Network, Inc.
Prognos
Zebra Medical Vision
Global Artificial Intelligence in Cancer Market: Regions
Global Artificial Intelligence in Cancer market is segmented based on regional analysis intfive major regions. These include North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. Global AI in Cancer in North America held the largest market share in the year 2020. However, The APAC market is expected tgrow at the fastest rate over the forecast period, owing temerging market growth strategies, improved medical diagnostic infrastructure, an ageing population, rising cancer prevalence, favorable government initiatives for AI in healthcare, and an increase in the number of COVID-19 positive patients.
Global Artificial Intelligence in Cancer Market is further segmented by region into:
North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany and Rest of Europe
Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – China, Japan, Australia and Rest of APAC
Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
Global Artificial Intelligence in Cancer Market report alscontains analysis on:
Artificial Intelligence in Cancer Segments:
By Surgery
Radiotherapy
Chemotherapy
Immunotherapy
Targeted Therapy
Phototherapy
Gene Therapy
Sonodynamic Therapy
By Cancer Type
Breast cancer
Lung cancer
Melanoma cancer
Colorectal cancer
Prostate cancer
Others
By End User
Diagnosis
Therapy
Prognosis
Health Management
Research
Artificial Intelligence in Cancer Market Dynamics
Artificial Intelligence in Cancer Market Size
Supply & Demand
Current Market Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
1. EXECUTIVE SUMMARY
2. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Latin America: (Brazil, Mexico, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Surgery: Market Share (2020-2030F)
12.2.1. Radiotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Chemotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Immunotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Targeted Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.5. Phototherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.6. Gene Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.7. Sonodynamic Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Cancer type: Market Share (2020-2030F)
12.3.1. Breast cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Lung cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Melanoma cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. Colorectal cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.5. Prostate cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By End-User: Market Share (2020-2030F)
12.4.1. Diagnosis, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Prognosis, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.4. Health Management, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.5. Research, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. COMPANY PROFILE
14. MICROSOFT CORPORATION
14.1. Company Overview
14.2. Company Total Revenue (Financials)
14.3. Market Potential
14.4. Global Presence
14.5. Key Performance Indicators
14.6. SWOT Analysis
14.7. Product Launch
15. NVIDIA
16. IBM
17. INTEL
18. SIEMENS HEALTHINEERS
19. GE HEALTHCARE
20. DIGITAL DIAGNOSTICS
21. XILINX
22. INFORMAI
23. ENLITIC
24. DAY ZERO DIAGNOSTICS
25. AIDENCE
26. BUTTERFLY NETWORK, INC.
27. PROGNOS
28. ZEBRA MEDICAL VISION
Consultant Recommendation
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Latin America: (Brazil, Mexico, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Surgery: Market Share (2020-2030F)
12.2.1. Radiotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Chemotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Immunotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Targeted Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.5. Phototherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.6. Gene Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.7. Sonodynamic Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Cancer type: Market Share (2020-2030F)
12.3.1. Breast cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Lung cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Melanoma cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. Colorectal cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.5. Prostate cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By End-User: Market Share (2020-2030F)
12.4.1. Diagnosis, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Prognosis, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.4. Health Management, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.5. Research, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. COMPANY PROFILE
14. MICROSOFT CORPORATION
14.1. Company Overview
14.2. Company Total Revenue (Financials)
14.3. Market Potential
14.4. Global Presence
14.5. Key Performance Indicators
14.6. SWOT Analysis
14.7. Product Launch
15. NVIDIA
16. IBM
17. INTEL
18. SIEMENS HEALTHINEERS
19. GE HEALTHCARE
20. DIGITAL DIAGNOSTICS
21. XILINX
22. INFORMAI
23. ENLITIC
24. DAY ZERO DIAGNOSTICS
25. AIDENCE
26. BUTTERFLY NETWORK, INC.
27. PROGNOS
28. ZEBRA MEDICAL VISION
Consultant Recommendation
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
